You are viewing a free preview of this lesson.
Subscribe to unlock all 10 lessons in this course and every other course on LearningBro.
Biological explanations account for addiction in terms of brain systems, neurochemistry and genetic predisposition, treating dependence as a consequence of the way addictive substances and behaviours act on the brain's natural reward circuitry. Their central claim is that addiction is, in large part, a brain condition: repeated activation of the reward system by an addictive substance or behaviour produces lasting neuroadaptations that drive craving, tolerance and withdrawal, and genetic differences make some people more vulnerable than others. This lesson develops three strands — genetic vulnerability (the evidence from twin, adoption and family studies for a heritable component), neurochemistry (the dopamine reward pathway running through the nucleus accumbens), and the role of tolerance and neuroadaptation in maintaining dependence. These explanations matter because they help account for why addiction is so resistant to willpower, and why several effective treatments are pharmacological. The topic is treated clinically and objectively, in the standard academic register expected at A-Level.
Key Definition: The mesolimbic dopamine pathway is the brain's principal reward circuit, running from the ventral tegmental area (VTA) in the midbrain to the nucleus accumbens, with projections to the prefrontal cortex. It is activated by naturally rewarding experiences and is powerfully engaged ("hijacked") by addictive substances and behaviours.
This lesson addresses the Edexcel 9PS0 — Paper 2, Topic 8: Health Psychology content on the biological explanation of addiction: genetic vulnerability (heritability evidence from twin, adoption and family studies; candidate genes affecting the dopamine system); the neurochemistry of reward (the dopamine reward pathway, the ventral tegmental area and nucleus accumbens, and how addictive substances and gambling engage it); and the role of tolerance and neuroadaptation in the development and maintenance of dependence. In assessment-objective terms, you should be able to describe the reward pathway, the genetic evidence and the neuroadaptation account of tolerance (AO1), apply this explanation to a described individual or scenario — for example, interpreting a described family history or the pattern of an individual's drug use (AO2), and evaluate the biological explanation, including its strong pharmacological support, the charge of reductionism, and the predisposition-versus-determinism issue for genetics (AO3).
Connects to…
Naturally rewarding experiences — eating when hungry, drinking when thirsty, social bonding, sex — activate the mesolimbic dopamine pathway:
This circuit is evolutionarily ancient: it evolved to reinforce survival- and reproduction-promoting behaviours by making them feel rewarding, so that they are repeated. Dopamine in this system is best understood not simply as a "pleasure chemical" but as a signal of reward and incentive salience — it tags experiences (and the cues that predict them) as important and worth pursuing, which is why it is so central to motivation and to addiction.
Key Definition: The nucleus accumbens is a structure in the ventral striatum that is central to reward and motivation; dopamine release into it signals that an experience is rewarding and worth repeating, and its activation is a common final pathway for both natural rewards and addictive substances.
The foundational evidence that the brain contains a reward system comes from Olds and Milner (1954). Working with rats, they implanted electrodes into specific brain regions (including areas of the limbic system associated with the reward pathway) and allowed the animals to deliver electrical stimulation to their own brains by pressing a lever. Their striking finding was that rats would press the lever repeatedly and persistently to obtain stimulation of these regions — in some cases to the exclusion of eating and drinking — indicating that the stimulation was powerfully rewarding. The conclusion was that the brain contains identifiable reward centres whose activation is intensely reinforcing. This landmark study established that reward has a specific neural basis, and it laid the groundwork for the modern understanding that addictive substances produce their effects by engaging this same natural reward circuitry.
A useful refinement, drawn from the incentive-salience account, is the distinction between "liking" (the actual pleasure obtained from a reward) and "wanting" (the dopamine-driven motivation to obtain it). In addiction these can come apart: as tolerance develops, the liking (pleasure) often fades while the wanting (craving, compulsive seeking) becomes ever stronger, because the reward system has become sensitised to the substance and its cues. This helps explain the otherwise puzzling clinical observation that long-term users may report getting little real enjoyment from the substance yet feel an overwhelming compulsion to take it. Alongside this, repeated reward-pathway activation is associated with reduced regulatory control by the prefrontal cortex, which normally weighs long-term consequences and inhibits impulsive action; as prefrontal control weakens relative to a sensitised reward and craving system, the capacity to resist use is undermined — a neural picture of the "loss of control" that defines addiction.
Addictive drugs act on this circuit to produce dopamine release in the nucleus accumbens that is larger and more reliable than that produced by natural rewards. Because the dopamine signal also tags the cues that predict reward, the people, places and rituals surrounding substance use acquire strong incentive salience, helping to explain the craving and cue-driven relapse examined in the learning explanation.
Different drug classes reach this common endpoint by distinct pharmacological routes, which is worth knowing because it shows the reward pathway is a convergence point rather than a single lock that one key fits. Stimulants such as cocaine and amphetamine raise dopamine in the nucleus accumbens directly — cocaine by blocking the dopamine transporter that would normally reuptake dopamine from the synapse, amphetamine by additionally forcing its release — so the reward signal is amplified without the pathway's own regulation. Nicotine acts on nicotinic acetylcholine receptors located on the VTA dopamine neurons themselves, increasing their firing and so their dopamine output. Opioids such as heroin and morphine act more indirectly: they inhibit the inhibitory GABA interneurons that normally restrain the VTA, so disinhibiting the dopamine neurons and letting them fire more freely. Alcohol has a diffuse action across several systems (enhancing inhibitory GABA transmission and dampening excitatory glutamate), but it too ultimately increases accumbens dopamine. The unifying point is that chemically very different substances all converge on the same final reward signal — which is exactly why one neural account can span the whole substance category, and why the pathway, not any single receptor, is the heart of the biological explanation.
graph LR
A[Substance or Reward] --> B[VTA Activated]
B --> C[Dopamine Released into Nucleus Accumbens]
C --> D[Reward / Incentive Salience Signalled]
D --> E[Prefrontal Cortex Encodes Memory and Cues]
E --> F[Craving and Seeking Behaviour]
F --> A
Crucially, gambling shows that the biological explanation is not confined to ingested substances. Although no chemical enters the body, gambling activates the same mesolimbic dopamine reward pathway as drug rewards, which is central to why it is now grouped with the substance addictions. Three features are important:
These mechanisms explain why gambling can produce craving, escalation (a tolerance-like need to bet more for the same excitement) and compulsive continuation, paralleling substance addiction at the level of the reward system.
Biological explanations hold that genetic differences make some people more vulnerable to addiction. The evidence comes from three converging designs.
| Study design | Logic | Typical finding |
|---|---|---|
| Twin studies | Compare concordance in identical (MZ, ~100% shared genes) versus non-identical (DZ, ~50%) twins | Higher concordance for addiction in MZ than DZ twins, implying a genetic contribution |
| Adoption studies | Compare adoptees with their biological versus adoptive parents | Raised risk in the biological children of addicted parents, even when reared apart |
| Family studies | Examine whether addiction runs in families | Addiction clusters in families (but shared environment is a confound) |
Taken together, these designs point to a substantial heritable component to addiction (commonly described as accounting for a substantial proportion of the variance, though estimates vary by substance and study), while the residual is environmental. Candidate genes — particularly variants affecting the dopamine system, such as those influencing the DRD2 dopamine-receptor gene — have been implicated. The proposed reward-deficiency mechanism is that individuals with, for example, fewer D2 receptors gain less reward from everyday experiences and may be drawn to substances or behaviours that produce a stronger dopamine signal in order to reach a "normal" level of reward.
The reward-deficiency idea connects genetics directly to the reward-system account: if an individual inherits a dopamine system that delivers a weaker everyday reward signal, ordinary pleasures may feel muted, and substances that produce an unusually strong dopamine surge become correspondingly more attractive. Genes may also act more indirectly, by shaping temperament (impulsivity, sensation-seeking) and metabolism (how quickly a substance such as nicotine is broken down, which affects dosing patterns) — so genetic vulnerability is rarely specific to one drug but instead tilts the whole reward–temperament system towards dependence once exposure occurs.
The most-cited candidate-gene work centres on a specific variant of DRD2 called the Taq1A polymorphism, whose A1 allele is associated with a lower density of D2 dopamine receptors in the striatum — precisely the neural profile the reward-deficiency account predicts should raise vulnerability. Blum et al. (1990) reported that the A1 allele was present far more often in the post-mortem brains of people who had been severely alcohol-dependent than in controls, and later work extended the association to other addictions such as heavy smoking and cocaine dependence. This gives the reward-deficiency idea a concrete molecular candidate rather than a purely abstract one. It is important, though, to state the strength of this evidence carefully: the A1-allele association has not replicated consistently, its effect size is small, and it is neither necessary nor sufficient for addiction — many A1 carriers never become dependent and many dependent people lack it. It is best presented as one small, illustrative strand of a polygenic vulnerability rather than as "the alcoholism gene". Alongside these molecular studies, the behaviour-genetic evidence can be described qualitatively: twin studies of alcohol dependence, for example, typically report substantially higher concordance in identical than non-identical twins, and reviews place the heritability of alcohol and nicotine dependence in the region of one-half — a large genetic contribution, but one that by definition leaves an equally large role for the environment.
Crucially, addiction is polygenic — many genes each contribute a small effect — and no single "addiction gene" exists. Candidate-gene findings such as those for DRD2 have been inconsistent across studies, so genes are best described as conferring a predisposition that interacts with environment rather than determining addiction. The interaction is genuinely two-way: genetic vulnerability raises the impact of environmental exposure (a gene–environment interaction), and predisposing traits may also lead individuals to seek out high-risk environments (a gene–environment correlation), which is one reason simple "how much is genetic?" questions are harder to answer than heritability figures suggest.
The biological explanation accounts for tolerance and withdrawal through neuroadaptation — the brain's adjustment to the persistent presence of a substance.
With repeated exposure, the brain attempts to restore balance by:
Because the brain is now adapted to the drug, the individual needs more of it to achieve the original effect (tolerance), and when the drug is removed the adapted brain is left unbalanced, producing the aversive withdrawal state. A useful theoretical framing is the idea of opposing processes: an initial drug-induced positive state (the A-process: euphoria, relaxation) is automatically countered by an opposing restorative state (the B-process: discomfort, craving). With repeated use the A-process weakens (tolerance) while the B-process grows stronger and longer-lasting, so the individual increasingly uses the drug to suppress the B-process (avoid withdrawal) rather than to enjoy the A-process — the neural basis of the shift from positive to negative reinforcement.
| Stage | A-Process (drug-induced pleasure) | B-Process (opposing withdrawal state) | Dominant motivation |
|---|---|---|---|
| Early use | Strong | Weak, short-lasting | Positive reinforcement (seeking the "high") |
| Chronic use | Weak (tolerance) | Strong, long-lasting | Negative reinforcement (avoiding withdrawal) |
Key Definition: Neuroadaptation is the process by which the brain adjusts to the sustained presence of a substance by altering neurotransmitter production, receptor density or metabolic activity. It is the neural basis of both tolerance and withdrawal.
Subscribe to continue reading
Get full access to this lesson and all 10 lessons in this course.